Back

We have so much waiting for you at SBS 2011

27th - 31st March. Booth #1225

With five exceptional posters and an inspiring tutorial, BioFocus can demonstrate a drug discovery offering has the ability to deliver success to your therapeutic programs.

View our 5 exceptional posters

  • Efficient hit finding approaches for HMTs - the key parameters (M111)
  • Selective HDAC4 inhibitors as potential therapeutics for Huntington's disease (M155)
  • Coupling automated electrophysiology with microfluidic perfusion to drive hit to lead and lead optimization studies for voltage- and ligand-gated ion channel targets (W528)
  • Fluorescence lifetime assays - an attractive addition to the toolbox of fragment screening technologies (T307)
  • EpiRoadmap: Integration of chemogenomics-based approaches for epigenetic targets (M200)

The proposed poster "Kinetic binding studies on the muscarinic M3 receptor using the Tag Lite platform", will now be covered in the CisBio tutorial on Wednesday 30th at 12:30 - 1: 25 pm.  The subject can also be discussed with BioFocus at booth #1225. 

Inspiring epigenetics tutorial

Epigenetics drug discovery: success delivered by BioFocus

Wednesday 30th, 8:00 – 8:50 am. Room Osceola 1/2

Presented by Doris Hafenbradl, Senior Director, BioFocus, Switzerland

BioFocus has identified novel chemotypes that have progressed into further optimization using intelligent high-throughput screening. The epigenetics drug discovery toolbox has been significantly expanded by:

  • Design of efficient and selective inhibitors of HMTs using proprietary chemogenomics tools
  • Hit characterization and selectivity profiling by orthogonal assay technologies

To find out more visit us at booth #1225





Print to HTML Print as PDF Send to a friend




BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.